These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 14993449

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.
    Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E.
    Trends Pharmacol Sci; 2009 Feb; 30(2):55-60. PubMed ID: 19110320
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. GABAergic dysfunction in mGlu7 receptor-deficient mice as reflected by decreased levels of glutamic acid decarboxylase 65 and 67kDa and increased reelin proteins in the hippocampus.
    Wierońska JM, Brański P, Siwek A, Dybala M, Nowak G, Pilc A.
    Brain Res; 2010 Jun 02; 1334():12-24. PubMed ID: 20353761
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Epigenetic model in the pharmacologic modulation of vulnerability to schizophrenia].
    Tremolizzo L.
    Encephale; 2007 Nov 02; 33(Pt 3):867-9. PubMed ID: 18402359
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.
    Dong E, Agis-Balboa RC, Simonini MV, Grayson DR, Costa E, Guidotti A.
    Proc Natl Acad Sci U S A; 2005 Aug 30; 102(35):12578-83. PubMed ID: 16113080
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation.
    Dong E, Grayson DR, Guidotti A, Costa E.
    Epigenomics; 2009 Oct 30; 1(1):201-11. PubMed ID: 22122643
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.
    Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E.
    Psychopharmacology (Berl); 2005 Jul 30; 180(2):191-205. PubMed ID: 15864560
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder.
    Veldic M, Kadriu B, Maloku E, Agis-Balboa RC, Guidotti A, Davis JM, Costa E.
    Schizophr Res; 2007 Mar 30; 91(1-3):51-61. PubMed ID: 17270400
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection.
    Ruzicka WB, Zhubi A, Veldic M, Grayson DR, Costa E, Guidotti A.
    Mol Psychiatry; 2007 Apr 30; 12(4):385-97. PubMed ID: 17264840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.